Literature DB >> 9619969

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.

E Talbott1, A Clerici, S L Berga, L Kuller, D Guzick, K Detre, T Daniels, R A Engberg.   

Abstract

Polycystic ovary syndrome (PCOS), a disorder of hyperandrogenism and chronic anovulation affects 5%-10% of all women. Women with PCOS often have elevated cardiovascular risk factors. A total of 244 PCOS cases were identified through the Division of Reproductive Endocrinology at Magee-Womens Hospital and were age-matched to 244 neighborhood controls. The average age of cases and controls was 35.3 +/- 7.4 and 36.7 +/- 7.7. Women with PCOS compared to controls had substantially higher LDL-C and total cholesterol levels at each age group under 45 years after adjustment for body mass index, hormone use, and insulin levels. In the over 40-year age group, little difference was noted between cases and controls. Among cases and controls (<40), PCOS predicted LDL-C, total cholesterol and triglycerides, but did not have a significant effect on lipid levels in older cases and controls after controlling for the other variables. The primarily pre- to perimenopausal PCOS cases > or =40 years of age have similar LDL-C and total cholesterol levels as their age-matched controls, probably reflecting the LDL-C increase with age among controls.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619969     DOI: 10.1016/s0895-4356(98)00010-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  58 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 3.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

Review 4.  Identification and treatment of metabolic complications in pediatric obesity.

Authors:  Katie Larson Ode; Brigitte I Frohnert; Brandon M Nathan
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

5.  Varying patterns of brachial artery flow-mediated dilatation in women with polycystic ovary syndrome and controls: An application of the group-based trajectory modeling.

Authors:  Michelle L Meyer; Ping G Tepper; Emma Barinas-Mitchell; Mary T Korytkowski; Evelyn O Talbott
Journal:  J Clin Ultrasound       Date:  2015-07-14       Impact factor: 0.910

Review 6.  Chinese herbal medicine for subfertile women with polycystic ovarian syndrome.

Authors:  Kunyan Zhou; Jing Zhang; Liangzhi Xu; Taixiang Wu; Chi Eung Danforn Lim
Journal:  Cochrane Database Syst Rev       Date:  2016-10-12

7.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 8.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

9.  Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.

Authors:  Brooke Rossi; Sara Sukalich; Jennifer Droz; Adam Griffin; Stephen Cook; Aaron Blumkin; David S Guzick; Kathleen M Hoeger
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

10.  Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome.

Authors:  Mohadetheh Moulana
Journal:  Life Sci       Date:  2019-01-29       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.